COSMOS Pharmaceutical Corporation
3349.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥1,011,390,000 | ¥964,989,000 | ¥827,697,000 | ¥755,414,000 |
| % Growth | 4.8% | 16.6% | 9.6% | – |
| Cost of Goods Sold | ¥798,109,000 | ¥776,683,000 | ¥658,979,000 | ¥603,966,000 |
| Gross Profit | ¥213,281,000 | ¥188,306,000 | ¥168,718,000 | ¥151,448,000 |
| % Margin | 21.1% | 19.5% | 20.4% | 20% |
| R&D Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| G&A Expenses | ¥107,000 | ¥116,000 | ¥128,000 | ¥127,000 |
| SG&A Expenses | ¥152,430,000 | ¥138,536,000 | ¥122,807,000 | ¥107,756,000 |
| Sales & Mktg Exp. | ¥1,561,000 | ¥1,812,000 | ¥1,648,000 | ¥1,632,000 |
| Other Operating Expenses | ¥20,447,000 | ¥18,269,000 | ¥15,782,000 | ¥13,895,000 |
| Operating Expenses | ¥172,877,000 | ¥156,805,000 | ¥138,589,000 | ¥121,651,000 |
| Operating Income | ¥40,404,000 | ¥31,501,000 | ¥30,128,000 | ¥29,796,000 |
| % Margin | 4% | 3.3% | 3.6% | 3.9% |
| Other Income/Exp. Net | ¥1,968,000 | ¥2,218,000 | ¥2,645,000 | ¥3,252,000 |
| Pre-Tax Income | ¥42,372,000 | ¥33,719,000 | ¥32,773,000 | ¥33,048,000 |
| Tax Expense | ¥11,393,000 | ¥9,265,000 | ¥8,975,000 | ¥9,892,000 |
| Net Income | ¥30,978,000 | ¥24,454,000 | ¥23,797,000 | ¥23,155,000 |
| % Margin | 3.1% | 2.5% | 2.9% | 3.1% |
| EPS | 390.85 | 308.61 | 300.48 | 292.37 |
| % Growth | 26.6% | 2.7% | 2.8% | – |
| EPS Diluted | 390.85 | 308.61 | 300.48 | 292.37 |
| Weighted Avg Shares Out | 79,257 | 79,240 | 79,198 | 79,198 |
| Weighted Avg Shares Out Dil | 79,257 | 79,240 | 79,198 | 79,198 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥48,000 | ¥44,000 | ¥47,000 | ¥52,000 |
| Interest Expense | ¥254,000 | ¥99,000 | ¥51,000 | ¥52,000 |
| Depreciation & Amortization | ¥22,229,000 | ¥19,924,000 | ¥17,368,000 | ¥15,110,000 |
| EBITDA | ¥64,855,000 | ¥53,744,000 | ¥50,192,000 | ¥48,210,000 |
| % Margin | 6.4% | 5.6% | 6.1% | 6.4% |